ScreenerHero

COAG Hemab Therapeutics Holdings, Inc.

NAS · US · Healthcare · Biotechnology · hemab.com
28.70USD+1.16%Mkt Cap: 1.34B $P/E: —

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.34B USD
Enterprise Value868.79M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-63.91M USD
Revenue/Share—
Last Price28.70 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees59
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-11.18
PEG—
EV/EBITDA-10.00
EV/Revenue—
P/S—
P/B2.92
EPS (TTM)-4.00
EPS (Forward)-2.54
52W Range
23.0018% of range55.42
52W High55.42 USD
52W Low23.00 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE36.18%
ROA-32.81%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-61.48M USD
CapEx (TTM)16.00K USD
FCF Margin—
FCF Yield—
Net Debt-456.43M USD
Net Debt/EBITDA5.25
Balance Sheet
Debt/Equity-0.01
Current Ratio35.85
Quick Ratio35.48
Book Value/Sh9.73 USD
Cash/Share9.79 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)61.20 USD
Upside (mean)+113.2%
Target Range58.00 USD – 65.00 USD
58.00+113.2% to mean65.00
# Analysts5
Ownership
Shares Out.46.71M
Float20.31M
Insiders10.78%
Institutions92.36%
Short Interest
Short Ratio7.5d
Short % Out.5.65%
Shares Short2.64M
Short (prev mo.)2.03M
Technical
SMA 5044.16 (-35.0%)
SMA 20037.35 (-23.2%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)544.49K
Avg Vol (10d)438.71K
Technical Indicators
RSI (14)21.0
MACD-4.0231
MACD Signal-3.4700
MACD Hist.-0.5531
BB Upper44.67 USD
BB Middle35.65 USD
BB Lower26.63 USD
BB Width50.61%
ATR (14)2.713 USD
Vol Ratio (20d)0.59x